Most cited papers from Summit (United Kingdom)

Summit (United Kingdom)

What are the most cited papers from Summit (United Kingdom)?

The most cited paper from Summit (United Kingdom) is "Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol" (Kausik Kumar Ray, R. Scott Wright, David G. Kallend et al., 2020), with 1,652 citations. Next come "Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia" (824) and "Novel targets for Huntington's disease in an mTOR-independent autophagy pathway" (797).

Published TypeFieldAccessCitations

Showing 50 of 59 papers. Every paper with more than 40 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol Kausik Kumar Ray, R. Scott Wright, David G. Kallend et al. · New England Journal of Medicine Open access	18 Mar 2020	1,652
2	Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia Frederick Johan Raal, David G. Kallend, Kausik Kumar Ray et al. · New England Journal of Medicine Open access	18 Mar 2020	824
3	Novel targets for Huntington's disease in an mTOR-independent autophagy pathway Andrea J. Williams, Sovan Sarkar, Paul A. Cuddon et al. · Nature Chemical Biology Open access	23 Mar 2008	797
4	Iminosugars past, present and future: medicines for tomorrow Graeme Horne, Francis X. Wilson, Jon M. Tinsley et al. · Drug Discovery Today	4 Sep 2010	323
5	Recommendations for reducing radiation exposure in myocardial perfusion imaging Manuel D. Cerqueira, Kevin C. Allman, Edward P. Ficaro et al. · Journal of Nuclear Cardiology	25 May 2010	313
6	Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery Teresa Pereira de Barros, Wendy K. ALDERTON, H. M. Reynolds et al. · British Journal of Pharmacology Open access	16 Jun 2008	276
7	Achieving asthma control in practice: Understanding the reasons for poor control John Haughney, David Price, Alan G. Kaplan et al. · Respiratory Medicine Open access	24 Sep 2008	232
8	Selection of Views to Materialize Under a Maintenance Cost Constraint Himanshu Gupta, Inderpal Singh Mumick · Lecture notes in computer science Conference paper	1999	218
9	Zebrafish: An in vivo model for the study of neurological diseases Jonathan D. Best · Neuropsychiatric Disease and Treatment Open access	Jun 2008	210
10	Zebrafish based assays for the assessment of cardiac, visual and gut function — potential safety screens for early drug discovery Stéphane Berghmans, Paul Butler, Paul Goldsmith et al. · Journal of Pharmacological and Toxicological Methods	9 Jun 2008	188
11	Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse Jonathon M. Tinsley, Rebecca J. Fairclough, Richard Storer et al. · PLoS ONE Open access	6 May 2011	180
12	Loss of PINK1 Function Affects Development and Results in Neurodegeneration in Zebrafish Oleg V. Anichtchik, Heike Diekmann, Angeleen Fleming et al. · Journal of Neuroscience Open access	13 Aug 2008	178
13	SUNtool – A new modelling paradigm for simulating and optimising urban sustainability Darren Robinson, Nittaya Campbell, W. Gaiser et al. · Solar Energy Open access	17 Jul 2007	168
14	Solar radiation modelling in the urban context Darren Robinson, Andrew Stone · Solar Energy	18 Jun 2004	165
15	The significance of the anthropogenic heat emissions of London's buildings: A comparison against captured shortwave solar radiation Ian Hamilton, Michael Davies, Philip Steadman et al. · Building and Environment	28 Jul 2008	127
16	Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study Richard J Vickers et al. · The Lancet Infectious Diseases Open access	28 Apr 2017	120
17	Machine learning-powered antibiotics phenotypic drug discovery Sannah Zoffmann, Maarten Vercruysse, Fethallah Benmansour et al. · Scientific Reports Open access	21 Mar 2019	117
18	Shared decision-making for people with asthma Kayleigh M Kew, Poonam R. Malik, Krishnan Aniruddhan et al. · Cochrane Database of Systematic Reviews Open access	3 Oct 2017	96
19	Brief Report: A Phase II b Trial of a Novel Extended‐Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis Philip G. Conaghan, Stanley B. Cohen, Françis Berenbaum et al. · Arthritis & Rheumatology Open access	31 Oct 2017	93
20	Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200 Daruka Mahadevan, Mark C. Lanasa, Charles Michael Farber et al. · Journal for ImmunoTherapy of Cancer Open access	23 Aug 2019	89
21	Validation of the use of zebrafish larvae in visual safety assessment Frances M. Richards, Wendy K. ALDERTON, G.M. Kimber et al. · Journal of Pharmacological and Toxicological Methods	4 May 2008	89
22	Therapeutic Applications of Iminosugars: Current Perspectives and Future Opportunities Graeme Horne, Francis X. Wilson · Progress in medicinal chemistry Book chapter	2011	88
23	Decreased BDNF Levels Are a Major Contributor to the Embryonic Phenotype of Huntingtin Knockdown Zebrafish Heike Diekmann, Oleg V. Anichtchik, Angeleen Fleming et al. · Journal of Neuroscience Open access	4 Feb 2009	85
24	Second-generation compound for the modulation of utrophin in the therapy of DMD Simon Guiraud, Sarah E. Squire, Benjamin Edwards et al. · Human Molecular Genetics Open access	May 2015	82
25	A simplified radiosity algorithm for general urban radiation exchange Darren Robinson, Andrew Stone · Building Services Engineering Research and Technology Open access	Nov 2005	82
26	Discovery of 2-Arylbenzoxazoles as Upregulators of Utrophin Production for the Treatment of Duchenne Muscular Dystrophy Daniel Chancellor et al. · Journal of Medicinal Chemistry	4 Apr 2011	80
27	Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects Clare E. Buckley, Anita Marguerie, Alan G. Roach et al. · Neuropharmacology	6 May 2010	80
28	Predicting the urban solar fraction: a methodology for energy advisers and planners based on GIS Stuart Gadsden, Mark Rylatt, Kevin John Lomas et al. · Energy and Buildings Open access	11 Nov 2002	78
29	Temporal dynamics of myelination in the zebrafish spinal cord Clare E. Buckley, Anita Marguerie, Wendy K. ALDERTON et al. · Glia	5 Feb 2010	77
30	Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors Marie Futter, H Diekmann, Erik Schoenmakers et al. · Journal of Medical Genetics Open access	17 May 2009	73
31	Discovery and Exploitation of Inhibitor-resistant Aurora and Polo Kinase Mutants for the Analysis of Mitotic Networks Paul J. Scutt, Matthew Ling-Hon Chu, Dominic A. Sloane et al. · Journal of Biological Chemistry Open access	10 Apr 2009	69
32	Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification Kristin E. Wilson, Crystal Faelan, Janet C. Patterson‐Kane et al. · Toxicologic Pathology Open access	Oct 2017	68
33	Ethics of Using Smart City AI and Big Data: The Case of Four Large European Cities Mark Ryan, Gregory Anya · ORBIT Journal Open access	2019	66
34	Carbon emissions and decarbonisation: The role and relevance of fermentation industry in chemical sector Deepti Agrawal, Kelvin Awani, Seyed Ali Nabavi et al. · Chemical Engineering Journal Open access	27 Sep 2023	64
35	Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin Cheleste M. Thorpe, Anne V Kane, Justin H. Chang et al. · PLoS ONE Open access	2 Aug 2018	57
36	Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies Narinder Janghra, Jennifer Elizabeth Morgan, Caroline A. Sewry et al. · PLoS ONE Open access	14 Mar 2016	57
37	Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy Valeria Ricotti, Stefan Spinty, Helen Roper et al. · PLoS ONE Open access	7 Apr 2016	55
38	Impact on toxin production and cell morphology inClostridium difficileby ridinilazole (SMT19969), a novel treatment forC. difficileinfection Eugénie Bassères, Bradley T. Endres, Mohammed Khaleduzzaman et al. · Journal of Antimicrobial Chemotherapy Open access	18 Feb 2016	55
39	Looking glass inhibitors: scalable syntheses of DNJ, DMDP, and (3R)-3-hydroxy-l-bulgecinine from d-glucuronolactone and of l-DNJ, l-DMDP, and (3S)-3-hydroxy-d-bulgecinine from l-glucuronolactone. DMDP inhibits β-glucosidases and β-galactosidases whereas l-DMDP is a potent and specific inhibitor of α-glucosidases Daniel Best, Chen Wang, Alexander C. Weymouth‐Wilson et al. · Tetrahedron Asymmetry	Mar 2010	55
40	An overview of a free–market approach to climate change and conservation Richard L. Sandor, Eric C. Bettelheim, Ian R. Swingland · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences	28 Jun 2002	55
41	Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid Isabel V. L. Wilkinson, Kelly J. Perkins, Hannah F. Dugdale et al. · Angewandte Chemie International Edition Open access	22 Nov 2019	53
42	Ridinilazole: a novel therapy for Clostridium difficile infection Richard J Vickers, Glenn Tillotson, Ellie J. C. Goldstein et al. · International Journal of Antimicrobial Agents Open access	31 May 2016	53
43	Putting solar energy on the urban map: a new GIS-based approach for dwellings Stuart Gadsden, Mark Rylatt, Kevin John Lomas · Solar Energy Open access	May 2003	53
44	Steviamine, a new indolizidine alkaloid from Stevia rebaudiana Agnieszka Michalik, Jacqueline Hollinshead, Laurence Jones et al. · Phytochemistry Letters	26 Apr 2010	52
45	The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy Simon Guiraud, David Roblin, Davies. E. Kay · Expert Opinion on Orphan Drugs Open access	8 Feb 2018	50
46	Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers Jon M. Tinsley, Neil M. Robinson, Kay Elizabeth Davies · The Journal of Clinical Pharmacology Open access	4 Feb 2015	48
47	Synthesis of the naringinase inhibitors l-swainsonine and related 6-C-methyl-l-swainsonine analogues: (6R)-C-methyl-l-swainsonine is a more potent inhibitor of l-rhamnosidase by an order of magnitude than l-swainsonine Anders E. Håkansson, Jeroen van Ameijde, Graeme Horne et al. · Tetrahedron Letters	27 Nov 2007	48
48	Automated Large-Scale Culture and Medium-Throughput Chemical Screen for Modulators of Proliferation and Viability of Human Induced Pluripotent Stem Cell–Derived Neuroepithelial-like Stem Cells Donna McLaren, Thorsten Gorba, Anita Marguerie de Rotrou et al. · SLAS DISCOVERY Open access	6 Oct 2012	47
49	Tau Pathology is PresentIn Vivoand DevelopsIn Vitroin Sensory Neurons from Human P301S Tau Transgenic Mice: A System for Screening Drugs against Tauopathies Manuela Mellone, Dimitra Kestoras, Melissa R. Andrews et al. · Journal of Neuroscience Open access	13 Nov 2013	47
50	Targeted microbiome-sparing antibiotics Tim Avis, Francis X. Wilson, Nawaz Khan et al. · Drug Discovery Today Open access	28 Jul 2021	46

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.